Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis gets EC approval for Apidra

The European Commission has approved sanofi-aventis drug, Apidra, for the control of hyperglycemia in adolescents and children over six-years old with type I diabetes
The European Commission (EC) has approved sanofi-aventis drug, Apidra, for the control of hyperglycemia in adolescents and children over six-years old with type I diabetes.

Apidra, which has been developed for paediatric use, and can be used in combination with their standard basal insulin as part of their diabetes treatment plan. The EC granted sanofi-aventis approval for the drug after a review of a 26-week phase III, open-label, active control study which involved 572 children and adolescents with Type I diabetes.

"Sanofi-aventis recognises the many challenges faced by children with diabetes and their families," said Dr Riccardo Perfetti, senior medical director, diabetes-metabolism franchise at sanofi-aventis. "The rapid-acting insulin analog Apidra will be available to children 6 years and older with diabetes and we hope it will offer them an effective treatment of choice for their overall diabetes therapy."

Type I diabetes is the most severe form of the condition and causes the immune system to destroy the insulin-producing beta cells of the pancreas that regulate blood glucose. The international diabetes foundation estimates that there are 444,000 children globally with Type I diabetes and that there are 70,000 new cases diagnosed every year. Children diagnosed with the condition will need daily insulin injections for rest of their lives.

25th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics